124 related articles for article (PubMed ID: 38237887)
1. A novel antagonist of the CCL5/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation.
Chen L; Xu G; Song X; Zhang L; Chen C; Xiang G; Wang S; Zhang Z; Wu F; Yang X; Zhang L; Ma X; Yu J
Cancer Lett; 2024 Feb; 583():216635. PubMed ID: 38237887
[TBL] [Abstract][Full Text] [Related]
2. Endothelial cells promote triple-negative breast cancer cell metastasis
Zhang W; Xu J; Fang H; Tang L; Chen W; Sun Q; Zhang Q; Yang F; Sun Z; Cao L; Wang Y; Guan X
FASEB J; 2018 Jan; 32(1):276-288. PubMed ID: 28899878
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
Jin K; Pandey NB; Popel AS
Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
[TBL] [Abstract][Full Text] [Related]
4. An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia.
Norton KA; Wallace T; Pandey NB; Popel AS
BMC Syst Biol; 2017 Jul; 11(1):68. PubMed ID: 28693495
[TBL] [Abstract][Full Text] [Related]
5. CCR5-Mediated Signaling Is Involved in Invasion of Glioblastoma Cells in Its Microenvironment.
Novak M; Koprivnikar Krajnc M; Hrastar B; Breznik B; Majc B; Mlinar M; Rotter A; Porčnik A; Mlakar J; Stare K; Pestell RG; Lah Turnšek T
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545571
[TBL] [Abstract][Full Text] [Related]
6. CR5/CCL5 axis is linked to a poor outcome, and inhibition reduces metastasis in oral squamous cell carcinoma.
González-Arriagada WA; Coletta RD; Lozano-Burgos C; García C; Maripillán J; Alcayaga-Miranda F; Godínez-Pacheco B; Oyarce-Pezoa S; Martínez-Flores R; García IE
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17335-17346. PubMed ID: 37831273
[TBL] [Abstract][Full Text] [Related]
7. The potential to target CCL5/CCR5 in breast cancer.
Velasco-Velázquez M; Xolalpa W; Pestell RG
Expert Opin Ther Targets; 2014 Nov; 18(11):1265-75. PubMed ID: 25256399
[TBL] [Abstract][Full Text] [Related]
8. Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer.
Banerjee SM; Acedo P; El Sheikh S; Harati R; Meecham A; Williams NR; Gerard G; Keshtgar MRS; MacRobert AJ; Hamoudi R
Front Immunol; 2023; 14():1188087. PubMed ID: 38022682
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
Front Immunol; 2019; 10():757. PubMed ID: 31031757
[TBL] [Abstract][Full Text] [Related]
10. Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme.
Kranjc MK; Novak M; Pestell RG; Lah TT
Radiol Oncol; 2019 Nov; 53(4):397-406. PubMed ID: 31747383
[TBL] [Abstract][Full Text] [Related]
11. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.
Casagrande N; Borghese C; Visser L; Mongiat M; Colombatti A; Aldinucci D
Haematologica; 2019 Mar; 104(3):564-575. PubMed ID: 30309853
[TBL] [Abstract][Full Text] [Related]
12. Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis.
Pervaiz A; Zepp M; Georges R; Bergmann F; Mahmood S; Faiza S; Berger MR; Adwan H
J Cancer Res Clin Oncol; 2021 Jan; 147(1):73-91. PubMed ID: 32902795
[TBL] [Abstract][Full Text] [Related]
13. Vitamin C Inhibits Triple-Negative Breast Cancer Metastasis by Affecting the Expression of YAP1 and Synaptopodin 2.
Gan L; Camarena V; Mustafi S; Wang G
Nutrients; 2019 Dec; 11(12):. PubMed ID: 31817810
[TBL] [Abstract][Full Text] [Related]
14. Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
Song X; Zhou X; Qin Y; Yang J; Wang Y; Sun Z; Yu K; Zhang S; Liu S
Int J Mol Med; 2018 Jul; 42(1):579-588. PubMed ID: 29693154
[TBL] [Abstract][Full Text] [Related]
15. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells.
Singh SK; Mishra MK; Eltoum IA; Bae S; Lillard JW; Singh R
Sci Rep; 2018 Jan; 8(1):1323. PubMed ID: 29358632
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.
Aldinucci D; Casagrande N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772686
[TBL] [Abstract][Full Text] [Related]
17. CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer.
Pervaiz A; Zepp M; Mahmood S; Ali DM; Berger MR; Adwan H
Cell Oncol (Dordr); 2019 Feb; 42(1):93-106. PubMed ID: 30456574
[TBL] [Abstract][Full Text] [Related]
18. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
Wang SW; Liu SC; Sun HL; Huang TY; Chan CH; Yang CY; Yeh HI; Huang YL; Chou WY; Lin YM; Tang CH
Carcinogenesis; 2015 Jan; 36(1):104-14. PubMed ID: 25330803
[TBL] [Abstract][Full Text] [Related]
19. Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia.
Lin S; Wan S; Sun L; Hu J; Fang D; Zhao R; Yuan S; Zhang L
Cancer Sci; 2012 May; 103(5):904-12. PubMed ID: 22380870
[TBL] [Abstract][Full Text] [Related]
20. Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.
Sax MJ; Gasch C; Athota VR; Freeman R; Rasighaemi P; Westcott DE; Day CJ; Nikolic I; Elsworth B; Wei M; Rogers K; Swarbrick A; Mittal V; Pouliot N; Mellick AS
Oncotarget; 2016 Dec; 7(51):85437-85449. PubMed ID: 27863423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]